Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $628.49 million. The enterprise value is $643.06 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, before market open.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 337.90 million shares outstanding. The number of shares has increased by 10.77% in one year.
| Current Share Class | 337.90M |
| Shares Outstanding | 337.90M |
| Shares Change (YoY) | +10.77% |
| Shares Change (QoQ) | +2.74% |
| Owned by Insiders (%) | 1.59% |
| Owned by Institutions (%) | 18.09% |
| Float | 332.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 142.42 |
| Forward PS | 285.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 145.72 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06
| Current Ratio | 1.06 |
| Quick Ratio | 0.81 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -12.26 |
Financial Efficiency
Return on equity (ROE) is -776.89% and return on invested capital (ROIC) is -95.62%.
| Return on Equity (ROE) | -776.89% |
| Return on Assets (ROA) | -63.10% |
| Return on Invested Capital (ROIC) | -95.62% |
| Return on Capital Employed (ROCE) | -310.56% |
| Weighted Average Cost of Capital (WACC) | 19.35% |
| Revenue Per Employee | $38,043 |
| Profits Per Employee | -$584,879 |
| Employee Count | 116 |
| Asset Turnover | 0.07 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +186.68% in the last 52 weeks. The beta is 2.81, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 2.81 |
| 52-Week Price Change | +186.68% |
| 50-Day Moving Average | 1.77 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 48.91 |
| Average Volume (20 Days) | 12,316,162 |
Short Selling Information
The latest short interest is 52.36 million, so 15.50% of the outstanding shares have been sold short.
| Short Interest | 52.36M |
| Short Previous Month | 50.59M |
| Short % of Shares Out | 15.50% |
| Short % of Float | 15.75% |
| Short Ratio (days to cover) | 5.78 |
Income Statement
In the last 12 months, Ocugen had revenue of $4.41 million and -$67.85 million in losses. Loss per share was -$0.23.
| Revenue | 4.41M |
| Gross Profit | -35.34M |
| Operating Income | -63.58M |
| Pretax Income | -67.85M |
| Net Income | -67.85M |
| EBITDA | -61.19M |
| EBIT | -63.58M |
| Loss Per Share | -$0.23 |
Full Income StatementBalance Sheet
The company has $18.57 million in cash and $33.14 million in debt, with a net cash position of -$14.57 million or -$0.04 per share.
| Cash & Cash Equivalents | 18.57M |
| Total Debt | 33.14M |
| Net Cash | -14.57M |
| Net Cash Per Share | -$0.04 |
| Equity (Book Value) | -12.17M |
| Book Value Per Share | -0.04 |
| Working Capital | 1.30M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$56.96 million and capital expenditures -$185,000, giving a free cash flow of -$57.15 million.
| Operating Cash Flow | -56.96M |
| Capital Expenditures | -185,000 |
| Depreciation & Amortization | 2.39M |
| Net Borrowing | -1.00M |
| Free Cash Flow | -57.15M |
| FCF Per Share | -$0.17 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,440.74% |
| Pretax Margin | -1,537.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.77% |
| Shareholder Yield | -10.77% |
| Earnings Yield | -10.80% |
| FCF Yield | -9.09% |
Analyst Forecast
The average price target for Ocugen is $9.75, which is 424.19% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.75 |
| Price Target Difference | 424.19% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 229.31% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -14.49 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -14.49 |
| Piotroski F-Score | 2 |
